Novel agents that target ERα signaling as well as estrogen production without agonist activities will be desirable for breast cancer chemoprevention and treatment, and for women who have finished the prescribed course of tamoxifen [12-15]. The gene discussed is ESR1; the disease is breast carcinoma.